DailyIQ
Last updatedUpdating…

GEHC·GE HealthCare Technologies Inc.

$64.74
-0.03 (-0.05%)
High
$65.44
Open
$64.93
Market Cap
29.69B
52W High
$89.77
Low
$64.03
P. Close
$64.74
P/E
14.96
52W Low
$58.75
Fwd P/E
11.98
DailyIQ Est.
$85.13
Inst. Ownership
39.6%
Short Interest
3.68%
Days to Cover
5.5
Technical Score (1D)
36
BEARISH
News Sentiment
56
BULLISH
On Oct 7, GE HealthCare announced that it would release its third‑quarter 2026 financial results on Oct 28, 2026, with a live conference call and webcast scheduled for 8:30 a.m. Eastern Time. The announcement contained standard earnings details and did not include any guidance changes or material updates, indicating a routine quarterly reporting activity. The following day, on Oct 6, GE HealthCare disclosed a definitive $945 million cash purchase of SOFIE Biosciences, a U.S. contract manufacturing organization that focuses on PET radiopharmaceuticals. The acquisition is intended to create a final‑mile supply chain in the United States and is expected to close in the first half of 2027, pending regulatory approval. Management said the deal would add low‑double‑digit growth to GE HealthCare’s radiopharma portfolio and strengthen supply reliability, expanding the company’s manufacturing footprint in the U.S., Europe, and Japan. The transaction is also aimed at improving patient access to next‑generation precision‑care products such as Flyrcado. Both developments were reported as routine corporate actions without any immediate impact on the company’s financial outlook.
LOW TARGET
$70 +8.1%
2 analysts
MEAN TARGET
$83 +28.3%
15 analysts
HIGH TARGET
$96 +48.3%
13 analysts
PRICE RANGE
$70.00 - $96.00
SB / B / H / S / SS
8/11/9/1/1
DAILYIQ EST.
$85.13 (+31.5%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NMS
Country
United States
Symbol
GEHC
Description
GE HealthCare Technologies Inc. is a global leader in medical technology, specializing in diagnostic imaging, patient monitoring, and pharmaceutical diagnostics. The company's core business revolves around providing innovative products, services, and digital solutions designed to improve patient care across a range of clinical areas. GEHC's diverse portfolio includes advanced imaging systems like CT and MR scanners, ultrasound devices, and patient monitoring equipment. Furthermore, the company develops and markets pharmaceutical diagnostics, including contrast media and radiopharmaceuticals, that enhance the effectiveness of imaging procedures. Operating through four key segments, GE HealthCare Technologies Inc. is committed to advancing healthcare through technological innovation and comprehensive solutions.
Bought (1Y)
10,000 shares
$642K
Sold (1Y)
39,154 shares
$2.7M
Grogan William KChief Financial Officer
Award/Grant31,877 shares2026-09-14
Grogan William KChief Financial Officer
Award/Grant12,840 shares2026-09-14
Grogan William KChief Financial Officer
Award/Grant62,256 shares2026-09-14
Arduini Peter JPresident and CEO
Tax Withholding6,303 shares2026-09-03
Estrampes CatherineChief Commer. & Growth Officer
Tax Withholding508 shares2026-09-03
71/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
40.0%
Net Margin
10.1%
Revenue CAGR
4.1%
Current Ratio
1.37x
Debt / Equity
0.96x
Return on Equity
20.1%
Earnings Summary
GE HealthCare Technologies Inc. is a global leader in medical technology, delivering diagnostic imaging, patient monitoring, and pharmaceutical diagnostics solutions across clinical settings, operating within the broader healthcare and medical devices sector. The company’s portfolio spans advanced imaging systems such as CT and MR scanners, ultrasound devices, and patient monitoring equipment, complemented by a growing pharmaceutical diagnostics segment that includes contrast media and radiopharmaceuticals. In the most recent quarters, GEHC posted EPS of $1.45 in Q4 2024 and $1.01 in Q1 2025, both beating analyst expectations of $1.26 and $0.91 respectively; revenue in Q4 2024 reached $5.32 billion, slightly below the $5.73 billion estimate but still higher than the $4.78 billion in Q1 2025. The company’s EPS growth accelerated from $1.06 in Q2 2025 to $1.07 in Q3 2025, while revenue trended upward from $5.01 billion to $5.14 billion, indicating a modest but consistent expansion. Historically, GEHC has maintained a YoY revenue growth trajectory, with revenue rising from $5.10 billion in Q1 2024 to $5.69 billion in Q1 2025, and EPS has generally outpaced estimates, achieving a 3‑out‑of‑4 quarter beat pattern over the past year. The company’s earnings have shown resilience even when revenue estimates were missed, suggesting strong underlying profitability. Recent news highlights GEHC’s acquisition of Sofie Biosciences for $945 million, adding a U.S. network of contract manufacturing sites and cyclotrons that will enhance its radiopharmaceutical capabilities; analysts expect the deal to be accretive to revenue growth, adjusted EBIT margin, and adjusted EPS in the first full year of ownership.

EPS

EstBeatMiss
$0.84$1.01$1.18$1.35$1.52Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.20 - -
Q2'26$1.04$1.13+9.1%
Q1'26$1.05$0.99-5.7%
Q4'25$1.43$1.44+1.0%
Q3'25$1.05$1.07+2.2%
Q2'25$0.92$1.06+15.4%

Revenue

EstBeatMiss
$4.9B$5.1B$5.4B$5.6B$5.8BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$5.5B - -
Q2'26$5.4B$5.3B-1.4%
Q1'26$5.0B$5.1B+2.1%
Q4'25$5.7B$5.7B-0.4%
Q3'25 - $5.1B -
Q2'25 - $5.0B -

Market Data

GEHC Stock Snapshot

NEUTRAL36/100
$64.74−$0.03 (0.0%)
Market cap
29.69B
P/E ratio
15.0
Day range
$64.03 – $65.44
News sentiment
56/100 · Neutral
Analyst target
$83.05 (+28.3%)
Consensus
Buy · 30 analysts
52-week range+10.2% off low · -27.9% from high
$58.75$89.77
Price $64.74 DailyIQ Est. $85.13

GEHC is in a holding pattern - neither trend nor momentum has taken control. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Reverse DCF

What growth is priced into GEHC?

RICH

At today's price, GE HealthCare Technologies Inc. needs to grow free cash flow about 9.7% a year for the next 10 years to justify its valuation at a 8.44% cost of capital. Over its actual history it has compounded free cash flow at 0.4% a year, so the market is asking for 9.3 percentage points above its own delivered rate. On that basis GEHC looks priced above what its own growth record supports.

Implied FCF growth
9.7%
Historical FCF CAGR
0.4%
Growth gap
+9.3 pts
Verdict
RICH
Discount rate (WACC)
8.44%
Beta
0.98

Behaviour On Record

What GEHC's own history says about today's numbers

Realized volatility (21d)
24.7% 35th pct
Below its peak
-30.1%
vs 200-day average
-7.8%
Up days (1y)
50%

GE HealthCare Technologies Inc. is currently running 24.7% annualised volatility over the last 21 sessions. Measured against GEHC's own 4 years of daily returns rather than a market-wide average, that is the 35th percentile — on the quiet side for this stock, against a typical reading of 28.7%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

GEHC is trading -30.1% below its running peak. Across 3 full years on file, its median worst-drawdown-in-a-year was -27.6%, and the deepest was -37.8% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -7.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 25th percentile — a narrower gap than it typically runs. Over the past year GEHC closed higher on 50% of sessions, and it is currently 2 sessions into a rising streak.

Overnight risk is measurable too: GEHC has opened more than 2% away from the prior close in 20 of 952 sessions (2.1% of the time), with the largest gaps running +6.6% and -6.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, GEHC moved an average of 2.3% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.5% and a largest of -2.8%.

All figures computed from 953 daily closes between 2022-12-15 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against GEHC's own 4-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of GEHC's sector?

GE HealthCare Technologies Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (weakening).

Sector rank
#3 of 12
Sector state
Weakening
Sector rotation score
82

Options Market

What is the options market pricing for GEHC?

CallsPuts

For GE HealthCare Technologies Inc.'s nearest expiry (2026-10-09, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.60), with at-the-money implied volatility around 32.1%. The options market is pricing roughly a ±2.6% move by that expiry — a range of about $63.02–$66.34.

Put/call ratio (2026-10-09)
0.60
ATM implied volatility
32.1%
Total open interest
1,507
Expected move by 2026-10-09
±2.6% ($63.02–$66.34)

Analyst Rating Changes

Are analysts turning bullish or bearish on GEHC?

Needham most recently initiated coverage on GE HealthCare Technologies Inc. to Buy on Sep 22, 2026 with a price target of $93. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Needham — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 22, 2026NeedhamInitiatedBuy$93
Sep 17, 2026BTIGReiteratedBuy$79
Aug 19, 2026BTIGReiteratedBuy$79
Jul 31, 2026UBSMaintainedNeutral$67 → $73
Jul 30, 2026CitigroupMaintainedNeutral$69 → $75
Jul 30, 2026Evercore ISI GroupMaintainedOutperform$80 → $84
Jul 30, 2026Wells FargoMaintainedOverweight$75 → $85
Jul 29, 2026BTIGMaintainedBuy$75 → $79
Jul 17, 2026Hovde GroupInitiatedMarket Perform$14
Jul 16, 2026UBSMaintainedNeutral$69 → $67
Jul 9, 2026BMO CapitalInitiatedMarket Perform$70
Jun 23, 2026RBC CapitalInitiatedOutperform$80

GEHC Competitive Positioning

GE HealthCare Technologies Inc. (GEHC) is tracked alongside these names in Medical Devices on DailyIQ — ranked by market cap, with today's move alongside.

Held by These ETFs

GEHC is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.

News Sentiment Analysis

Sentiment gathered from recent headlines

56/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
GE HealthCare (GEHC) scheduled the release of its third‑quarter 2026 financial results for October 28, 2026, ahead of market opening. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day, with a replay available on its investor website. The announcement provides investors with the timing of the earnings report and related disclosures, but does not indicate any change in guidance or performance expectations.
What did this article say?
Barclays analyst Christopher Pasquale initiated coverage on GE HealthCare Technologies (NASDAQ:GEHC) on October 7, assigning an Overweight rating. The bank set a price target of $85 per share, signaling confidence in the company’s growth prospects. This move follows GEHC’s recent product launches and earnings beat, positioning the firm favorably within the medical technology sector.
What did this article say?
GE HealthCare Technologies Inc. announced a definitive $945 million cash purchase of SOFIE Biosciences, a U.S. contract manufacturing organization focused on PET radiopharmaceuticals. The deal will create a final‑mile supply chain in the United States and broaden GEHC’s presence in the growing radiopharmaceutical market. Management expects the acquisition to lift revenue growth, adjusted EBIT margin and earnings per share in the first full year after closing, which is projected for the first half of 2027 pending regulatory approval.
What did this article say?
GE Healthcare Technologies announced a $945 million cash purchase of Sofie Biosciences, a U.S. contract manufacturing organization for PET radiopharmaceuticals. The deal adds 15 CMO sites and 21 cyclotrons, giving GE Healthcare a U.S. production and distribution network for its radiopharmaceuticals. Sofie also provides U.S. rights to the phase‑3 FAPI‑74 tracer, which GE already holds outside the U.S. The acquisition is expected to enhance GE’s precision diagnostics portfolio and position the company for future commercialization of the tracer by 2029.
What did this article say?
GE HealthCare announced the acquisition of Sofie Biosciences for $945 million, adding 15 U.S. contract manufacturing sites and a theranostics-focused CDMO facility to its portfolio. The deal, expected to close in the first half of 2027, will broaden GE HealthCare’s presence in the radiopharmaceutical market and support the production of its existing F‑18 diagnostic agents, including Flyrcado. The transaction is an all‑cash purchase that enhances GE HealthCare’s ability to supply novel PET radiopharmaceuticals to patients across the United States.
What did this article say?
GE HealthCare announced it would acquire Sofie Biosciences for $945 million in an all‑cash deal expected to close in the first half of 2027. The purchase adds Sofie’s 15 U.S. contract manufacturing sites and its theranostics‑focused CDMO operations, expanding GE HealthCare’s footprint in the PET radiopharmaceutical market. Sofie already produces GE’s Flyrcado diagnostic agent, and the acquisition is intended to broaden access to novel radiopharmaceuticals for cancer and Alzheimer’s disease imaging.
What did this article say?
GE HealthCare Technologies announced on October 5 that it would acquire Sofie Biosciences for $945 million. The deal adds a PET radiopharmaceutical company to GE HealthCare’s pharmaceutical diagnostics unit, broadening its imaging‑agent portfolio. Sofie’s products are used in brain, heart, and cancer imaging, and the acquisition is expected to grow the unit’s revenue in the low double digits. The transaction expands GE HealthCare’s presence in the rapidly growing PET market and strengthens its end‑to‑end radiopharmaceutical capabilities.
What did this article say?
Citigroup analyst Joanne Wuensch lowered GE HealthCare Technologies’ price target from $75 to $71 while keeping a neutral rating. The downgrade reflects a reassessment of the company’s valuation relative to peers. The move signals a modest negative outlook for the stock, though no fundamental business changes were cited.
What did this article say?
On October 5, GE HealthCare announced its agreement to acquire Sofie Biosciences for $945 million in cash, expanding its presence in the U.S. radiopharmaceutical market. Sofie, a contract manufacturer of PET radiopharmaceuticals, will provide GE HealthCare with a U.S. manufacturing and distribution footprint for F‑18–labeled PET products. The acquisition is expected to close in the first half of 2027 and will be integrated into GE HealthCare’s pharmaceutical diagnostics business.
What did this article say?
GE Healthcare Technologies agreed to acquire Sofie Biosciences for $945 million in cash, adding a U.S. radiopharmaceutical manufacturing network of 15 contract manufacturing sites and 21 cyclotrons. The transaction is projected to be accretive to revenue growth, adjusted EBIT margin and adjusted EPS in the first full year. The acquisition will establish GEHC’s presence in the final‑mile U.S. PET supply chain and enhance its Pharmaceutical Diagnostics segment.

Technical Analysis

Real-time indicators across multiple timeframes

36
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $12.45B combined position · 14 adding, 9 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy52,275,76711.38%$4.29B2026-01-29
BlackRock, Inc.▲ Buy37,467,8438.16%$2.40B2026-08-07
Invesco Ltd.▲ Buy18,296,3503.98%$1.17B2026-08-14
Harris Associates L P▼ Sell15,329,6643.34%$981.25M2026-08-14
JPMorgan Chase & Co▲ Buy10,329,2642.25%$671.92M2026-08-12
Morgan Stanley▼ Sell6,223,3221.35%$398.36M2026-08-13
Norges Bank▼ Sell5,823,5241.27%$372.76M2026-08-12
Goldman Sachs Group Inc▲ Buy4,446,5650.97%$284.62M2026-08-14
Northern Trust Corp▼ Sell3,938,7480.86%$252.12M2026-08-13
Bank of America Corp▼ Sell3,249,7710.71%$208.02M2026-08-14
FMR LLC (Fidelity)▲ Buy3,155,0950.69%$201.96M2026-08-13
Trian Fund Management, L.P.▲ Buy3,085,3440.67%$197.49M2026-08-12
Citadel Advisors LLC• Hold3,051,6320.66%$195.33M2026-09-02
Temasek Holdings (Private) Ltd▼ Sell2,515,3930.55%$161.01M2026-08-07
D1 Capital Partners L.P.▲ Buy1,763,2840.38%$144.62M2026-02-17
Susquehanna International Group, LLP▲ Buy1,464,0670.32%$93.71M2026-08-14
Point72 Asset Management, L.P.▲ Buy1,457,8730.32%$93.32M2026-08-14
Wells Fargo & Company▼ Sell879,5160.19%$56.30M2026-08-14
Citigroup Inc▲ Buy850,3740.19%$54.43M2026-08-03
AQR Capital Management LLC▲ Buy696,0840.15%$44.33M2026-08-14
Suvretta Capital Management, LLC• Hold532,2800.12%$39.43M2025-08-14
Squarepoint Ops LLC▲ Buy601,7310.13%$38.52M2026-08-14
Gotham Asset Management, LLC▲ Buy584,3950.13%$37.41M2026-08-14
AllianceBernstein L.P.▼ Sell518,3460.11%$36.90M2026-08-14
D. E. Shaw & Co., Inc.▼ Sell418,0890.09%$26.76M2026-08-14
Q2 2026 flow:19.33M sh bought ($1.24B)6.01M sh sold ($393.16M)net +13.32M sh (+$845.63M)
Congressional Trading Activity
7 disclosed trades · ~$56.0K est. traded value · 3 buys, 4 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Terri A. SewellHouseAL07▼ Sell$1K - $15K2026-03-252026-04-21
Warren DavidsonHouseOH08▼ Sell$1K - $15K2026-03-232026-03-25
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-05-31
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-04-28
Austin ScottHouseGA08▼ Sell$1K - $15K2025-03-272025-08-13
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27